About us

Rarity Bioscience provides ultrasensitive multiplex assays for detecting rare nucleic acid sequences in biological samples like liquid biopsies for research, pharma and clinic. Our technology platform – Rarity superRCA – permits read-out based on flow cytometry and already existing instrumentation.

The company was founded 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.

Fast, sensitive and reliable mutation detection technology
for optimal clinical decisions at the right time
to improve patient outcome

Contact us